{"id":109,"date":"2025-06-03T10:00:00","date_gmt":"2025-06-03T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=109"},"modified":"2025-09-01T03:03:10","modified_gmt":"2025-09-01T03:03:10","slug":"china-bd-deal-2025hansoh-and-regeneron-enters-a-2-billion-usd-license-on-glp-1-gip-ra-hs-20094","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/109.html","title":{"rendered":"[China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1\/GIP Ra HS-20094"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p>Announced Date: 2025-06-02 (June 2, 2024)<\/p>\n\n\n\n<p>Asset Name: HS-20094<\/p>\n\n\n\n<p>Licensor: Hansoh (Hansoh Pharmaceuticals Group,  China)<\/p>\n\n\n\n<p>Licensee (Buyer): \u00a0Regeneron  (Regeneron Pharmaceuticals, Inc., USA)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: dual GLP-1\/GIP receptor agonist\u00a0 \uff08weekly subcutaneous injection\uff09<\/p>\n\n\n\n<p>Current Stage: Phase III, China\u00a0<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Hansoh Pharma has granted Regeneron  an exclusive clinical development and commercial rights outside of the Chinese Mainland,\u00a0Hong Kong and\u00a0Macau for HS-20094.<\/p>\n\n\n\n<p> <\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$80 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$1.93 billion,<\/p>\n\n\n\n<p>Total up to $2.01 billion.<\/p>\n\n\n\n<p>Future potential royalties for global net sales outside of the designated territories would be in the low double digits.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1\/GIP Receptor Agonist<\/p>\n\n\n\n<p><a href=\"https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-expands-clinical-stage-obesity-portfolio-strategic\">https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-expands-clinical-stage-obesity-portfolio-strategic<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-06-02 (June 2, 2024) Asset Name: HS-20094 Licensor: Hansoh (Hansoh Pharmaceuticals Group, China) Licensee &hellip; <a title=\"[China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1\/GIP Ra HS-20094\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/109.html\"><span class=\"screen-reader-text\">[China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1\/GIP Ra HS-20094<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-109","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=109"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/109\/revisions"}],"predecessor-version":[{"id":110,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/109\/revisions\/110"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}